USPTO serial 77519365
DREAMWELL
Reviewed by CopyMark Law Group
Status 606
- Filing date
- Status date
- Registration date
- —
- Examiner
- HETZEL, DANNEAN
- Law office
- INTENT TO USE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with DREAMWELL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer L. Whitelaw
JENNIFER L. WHITELAW WHITELAW LEGAL GROUP3838 TAMIAMI TRL N FL 3NAPLES, FL 34103-3590UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Botanical extracts for use in the manufacture of nutraceuticals; botanical extracts for use in the manufacture of nutraceuticals and pharmaceuticals; botanical extracts for use in the manufacture of nutraceuticals and pharmaceuticals; chemical extracts and active principles extracted from medicinal plants for use in the manufacture of nutraceuticals and pharmaceuticals, namely, chemical agents made from botanical extracts; chemical extracts and active principles extracted from medicinal plants for use in the pharmaceutical industry, namely, chemical agents made from botanical extracts or association of chemical extracts for use in the manufacture of pharmaceutical or nutraceutical products; botanical extracts for use in the manufacture of medicated preparations in the form of lotions, creams, and topical analgesics and anesthetics, tablets, capsules, pills, lozenges, inhalers, tincture, suppositories and ampule for injection; botanical extracts used in the manufacture of pharmaceutical preparations in the form of lotions, creams, and topical analgesics and anesthetics, tablets, capsules, pills, tincture, suppositories and ampule for injection; botanical extracts for use in the manufacture of pharmaceutical preparations in the form of lotions, creams, and topical analgesics and anesthetics, tablets, capsules, pills, tincture, suppositories and ampule for injection; botanicals and botanical blends, herbals and herbal blends, botanical extracts and botanical extract blends, flavor extracts and flavor extract blends, algal extracts and algal extract blends, all for use in the manufacture of nutritional supplements and vitamins; algal extracts or algal extract blends for use in the manufacture of nutritional and dietary supplements; algal extracts and algal extract blends, all for use in the manufacture of nutritional supplements and vitamins; mushroom, fungus, and spore extracts for use in food manufacture; herbal extracts and blends for use in medicinal foods or beverages; botanical extracts and blends for use in the manufacture of medicinal foods or beverages; medicinal herb extracts for use in the manufacture of lotions, creams, and topical analgesics and anesthetics, tablets, capsules, pills, lozenges, inhalers, tincture, suppositories and ampule for injection; botanical extracts for use in the manufacture of nutraceuticals, nutritional use, and pharmaceuticals | ACTIVE | — |
| 005 | Nutritional additives for medical purposes for use in foods and dietary supplements for human consumption; nutritional supplements; herbal products, namely, medicated skin and lip balms; herbal products, namely, ointments, oils, drinks, infusions, syrups, herbal extracts, poisons, tinctures for medical use in the treatment of strokes, infarcts and other cardiovascular and cerebrum diseases; herbal products, namely, mentholated ointments for medical use; oils, namely, mineral oil for use as a laxative; drinks, namely, meal replacement drinks; dietary supplement drinks, medicinal drinks, and fish oil for use as a dietary supplement and as a nutraceutical dietary supplement; syrups, namely, cough syrups; herbal products for medicinal purposes, namely, herbal extracts for use as nutritional and dietary supplements; herbal products for medicinal purposes, namely, herbal extracts and syrups; medicinal herb extracts; medicinal herb extracts for medical purposes; plant extracts for medical or pharmaceutical purposes; plant extracts for medical and nutritional purposes; plant extracts for medical and pharmaceutical purposes; medicinal herbal extracts sold as a component ingredient of pharmaceutical preparations in the form of lotions, creams, and topical analgesics and anesthetics, tablets, capsules, pills, tincture, suppositories and ampule for injection used to treat skin ailments, for infection, degenerative, muscular, pulmonary, skeletal, endocrine, immune, neurological, cardiovascular, metabolic, inflammatory or cancer conditions; botanical extracts sold as a component ingredient of pharmaceutical preparations in the form of lotions, creams, and topical analgesics and anesthetics, tablets, capsules, pills, tincture, suppositories and ampule for injection used to treat skin ailments, for infection, degenerative, muscular, pulmonary, skeletal, endocrine, immune, neurological, cardiovascular, metabolic, inflammatory, or cancer conditions; yeast extracts for medical or pharmaceutical purposes; yeast extracts for medical or nutraceutical purposes; herbal products, namely, herbal powders for nutritional purposes; herbal products, namely, herbal meal replacement powders for dietary and nutritional purposes; herbal products, namely, aromatherapy packs filled with herbs for the treatment of, or relief of symptoms in, infectious diseases and adverse human health conditions, namely, infection, degenerative, muscular, pulmonary, skeletal, endocrine, immune, neurological, cardiovascular, metabolic, inflammatory, or cancer conditions; herbal products, namely, aromatherapy packs containing herbs used for relief from headaches, insomnia and sinus discomfort; herbal products, namely, herbal powders sold as an integral ingredient of nutritional supplement drink mix for nutritional purposes; pharmaceuticals and nutraceuticals, namely, vitamins and food supplements; pharmaceutical preparations, namely, appetite suppressants and lipid lowering agents; food for diabetics, infants and enteral feeding; botanical extracts for nutritional use; botanical extracts for medical, veterinary, nutraceutical and pharmaceutical purposes; designer extracts, namely, herbal extracts for medical, veterinary and pharmaceutical purposes; botanicals and botanical blends, herbals and herbal blends, botanical extracts and botanical extract blends, flavor extracts and flavor extract blends, all sold as components of nutritional supplements and vitamins; nutritional oils not for cosmetic purposes; food supplements, namely, lipid concentrates for use as a dietary food supplement or for pharmaceutical or medicinal purposes; food supplements, namely, anti-oxidants; food for medically restricted diets; dietary supplements, namely, vitamins and mineral supplements; anti-cough drops; cough drops; cough expectorants; throat lozenges; cough lozenges; cough syrups; cough treatment preparations; cold sore treatment preparations; pharmaceutical antitussive-cold preparations; preparations for treating colds; analgesic preparations; analgesics; antipyretic analgesics; ibuprofen for use as an oral analgesic; multipurpose medicated antibiotic cream, analgesic balm and mentholated salve; oral analgesics; topical analgesics; pharmaceutical preparations for the treatment and prevention of herpes; vaccines for the treatment and prevention herpes; medical biological preparations for the treatment and prevention of herpes; pharmaceutical preparations for the treatment of herpes simplex infection; pharmaceutical capsules for the treatment of herpes simplex infection; homeopathic preparations for the treatment of herpes and cold sores; pharmaceutical preparations for the treatment of herpes viruses; medicated topical clear fluoride gel for the treatment of herpes virus during the physical manifestation of the virus; pharmaceutical preparations for the treatment of herpes simplex virus type I or type ii or herpes zoster virus, not in intravenous form; plant based antivirals; over-the-counter topical antivirals; pharmaceutical preparation with antiviral and/or antimicrobial properties for use in the treatment of herpetic keratitis, conjunctivitis, hiv retinopathy, viral influenza "flu", herpes simplex virus 1, herpes simplex virus 2, varicella zoster virus "herpes zoster" "shingles", cytomegalovirus, viral parainfluenza, adenovirus, viral encephalitis, viral meningitis, arbovirus, arenavirus, picornavirus, coronavirus, syntialvirus, viral infections, common colds caused by viruses, cold sores, human immunedeficiency virus "hiv", roseola infantum, human herpes iv; pharmaceutical preparations for the treatment of viral diseases and disorders, namely, herpes; pharmaceutical preparations for treating immune diseases induced by virus, namely, herpes, herpes zoster and aids; functional foods, namely, dietetic foods adapted for medical purposes, food for diabetics, infants and enteral feeding, food for medically restricted diets; functional beverages, namely, nutritionally fortified beverages; medicinal foods, namely, processed food for medical purposes; animal health products, namely, animal feed supplements, medicated animal feed, micro-nutrient animal feed, dietary supplements for animals, non-medicated additives for animal feed for use as nutritional supplements, nutritional drinks for animals, pharmaceutical preparations for animal skincare; plant extracts for medical, veterinary and pharmaceutical purposes; botanical extracts for medical, veterinary and pharmaceutical purposes; herbal extracts for medical, veterinary and pharmaceutical purposes; designer extracts, namely, plant, herbal and botanical extracts for medical, veterinary and pharmaceutical purposes; biodefense products in the nature of medicinal preparations for the treatment of, or relief of symptoms in, infectious diseases and adverse human health conditions caused by biological agents, namely, infections, degenerative conditions, muscular conditions, pulmonary conditions, skeletal deterioration, endocrine conditions, immune deficiency conditions, neurological deficiency conditions, cardiovascular conditions, metabolic conditions, inflammatory infections or cancer; nutritionally fortified beverages for immune enhancement; nutritionally fortified beverages with rice bran and wheat bran; algal products for medicinal purposes, namely, algal extracts or algal extract blends for use as nutritional and dietary supplements; algal products, namely, algal powders sold as an integral ingredient of nutritional supplement drink mix for nutritional purposes; algal products, namely, algal powders for nutritional purposes; algal extracts or algal extract blends for medical or pharmaceutical purposes | ACTIVE | — |
| 029 | Food beverages, namely, dairy-based food beverages, fruit-based food beverages, vegetable-based food beverages, dairy-based chocolate food beverages, soy-based food beverage used as a milk substitute, vegetable-based chocolate food beverages and peanut-based food beverages; milk beverages, namely, milk, milk beverages containing fruits, milk beverages with high milk content, milk based beverages containing fruit juice and milk beverages containing coffee; milk powder; milk powder for nutritional purposes; powdered milk for food purposes; functional foods, namely, dairy-based food beverages, fruit-based food beverages, vegetable-based food beverages, dairy-based chocolate food beverages, soy-based food beverage used as a milk substitute, vegetable-based chocolate food beverages, nut-based food beverages, milk, milk beverages containing fruits, milk beverages with high milk content, milk based beverages containing fruit juice, and milk beverages containing coffee; soy protein for use as a food additive | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by HerbalScience Group, LLC
- Other trademarks owned by HerbalScience Group, LLC
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 029
- Similar marks named DREAMWELL
- Prosecution event MAB6 explained
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 4, 2011 | MAB6 | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Apr 4, 2011 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Aug 31, 2010 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 22, 2010 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Jul 22, 2010 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Jul 22, 2010 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Dec 22, 2009 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Jul 23, 2009 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jun 30, 2009 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 10, 2009 | NPUB | NOTICE OF PUBLICATION | — |
| May 22, 2009 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| May 18, 2009 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 18, 2009 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 18, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 15, 2009 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 11, 2009 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 11, 2009 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 11, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 7, 2009 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Apr 17, 2009 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Apr 8, 2009 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Apr 1, 2009 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 1, 2009 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 1, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 30, 2009 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Mar 27, 2009 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Mar 27, 2009 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 27, 2009 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Mar 23, 2009 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 23, 2009 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 23, 2009 | ALIE | ASSIGNED TO LIE | — |
| Mar 20, 2009 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 22, 2008 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 22, 2008 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 22, 2008 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 16, 2008 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 15, 2008 | MPMK | NOTICE OF PSEUDO MARK MAILED | — |
| Jul 14, 2008 | NWAP | NEW APPLICATION ENTERED | — |